Trials / Unknown
UnknownNCT05747742
Effect of Different Intensities of Repeated Low-Level Red-Light Therapy on Choroidal and Retinal Blood Flow Among Adults
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- The Second People's Hospital of Foshan · Academic / Other
- Sex
- All
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this clinical trial is to evaluate the effect of different intensities of repeated low-level red-light (RLRL) therapy on the choroidal and retinal blood flow among adults.
Detailed description
Repeated low-level red-light (RLRL) therapy is an emerging innovative and non-invasive treatment for a variety of eye diseases. Notably, RLRL was found to be effective in thickening choroidal thickness in a 1-year randomized controlled trial, indicating its potential in modulating blood flow in the fundus. However, it remains unclear how long it takes for the RLRL to make a difference in fundus blood flow and whether there is a dose-response. The purpose of this study is to evaluate the different intensities of RLRL on the choroidal and retinal blood flow among adults. This study will be conducted with a randomized cross-over design with a total follow-up of 3 months. The RLRL therapy will be carried out in the study site under supervision according to a standard protocol. Ophthalmic examinations, including visual acuity, intraocular pressure, optical coherence tomography, optical coherence tomography angiography, spherical equivalent refraction, slit lamp, and biometrics will be evaluated at enrollment and during follow-ups.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | RLRL device | Crossover device (RLRL of 50% or 100% intensity - alternate to first group). Cross over arms after one month of use and one month of washout period. |
Timeline
- Start date
- 2023-03-03
- Primary completion
- 2023-06-01
- Completion
- 2023-06-27
- First posted
- 2023-02-28
- Last updated
- 2023-03-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05747742. Inclusion in this directory is not an endorsement.